202 related articles for article (PubMed ID: 30015297)
1. Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome.
Marco-Benedí V; Lamiquiz-Moneo I; Álvarez-Sala LA; Civeira F
Atherosclerosis; 2018 Aug; 275():342-345. PubMed ID: 30015297
[TBL] [Abstract][Full Text] [Related]
2. Molecular and functional characterization of familial chylomicronemia syndrome.
Teramoto R; Tada H; Kawashiri MA; Nohara A; Nakahashi T; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Atherosclerosis; 2018 Feb; 269():272-278. PubMed ID: 29153744
[TBL] [Abstract][Full Text] [Related]
3. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM
Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic algorithm for familial chylomicronemia syndrome.
Stroes E; Moulin P; Parhofer KG; Rebours V; Löhr JM; Averna M
Atheroscler Suppl; 2017 Jan; 23():1-7. PubMed ID: 27998715
[TBL] [Abstract][Full Text] [Related]
5. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
6. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.
Chyzhyk V; Brown AS
Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia.
Caddeo A; Mancina RM; Pirazzi C; Russo C; Sasidharan K; Sandstedt J; Maurotti S; Montalcini T; Pujia A; Leren TP; Romeo S; Pingitore P
Nutr Metab Cardiovasc Dis; 2018 Feb; 28(2):158-164. PubMed ID: 29288010
[TBL] [Abstract][Full Text] [Related]
8. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
[TBL] [Abstract][Full Text] [Related]
9. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.
Davidson M; Stevenson M; Hsieh A; Ahmad Z; Roeters van Lennep J; Crowson C; Witztum JL
J Clin Lipidol; 2018; 12(4):898-907.e2. PubMed ID: 29784572
[TBL] [Abstract][Full Text] [Related]
10. Reduced psychological distress in familial chylomicronemia syndrome after patient support group intervention.
Wilson LM; Cross RR; Duell PB
J Clin Lipidol; 2018; 12(1):240-242. PubMed ID: 29195809
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of therapeutic plasma exchange in reducing the incidence of recurrent pancreatitis related to familial chylomicronemia.
Fitts E; Lee PDK; Yates SG
Transfusion; 2019 Nov; 59(11):3324-3328. PubMed ID: 31568575
[TBL] [Abstract][Full Text] [Related]
12. Familial chylomicronemia and multifactorial chylomicronemia.
Muñiz-Grijalvo O; Diaz-Diaz JL
Clin Investig Arterioscler; 2021 May; 33 Suppl 2():56-62. PubMed ID: 34006355
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
Rabacchi C; Pisciotta L; Cefalù AB; Noto D; Fresa R; Tarugi P; Averna M; Bertolini S; Calandra S
Atherosclerosis; 2015 Jul; 241(1):79-86. PubMed ID: 25966443
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
[TBL] [Abstract][Full Text] [Related]
16. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
Chait A; Eckel RH
Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
[TBL] [Abstract][Full Text] [Related]
17. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
[TBL] [Abstract][Full Text] [Related]
18. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
Steinhagen-Thiessen E; Stroes E; Soran H; Johnson C; Moulin P; Iotti G; Zibellini M; Ossenkoppele B; Dippel M; Averna MR;
Atherosclerosis; 2017 Jul; 262():146-153. PubMed ID: 28284702
[TBL] [Abstract][Full Text] [Related]
19. Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.
Lin MH; Tian XH; Hao XL; Fei H; Yin JL; Yan DD; Li T
BMC Pregnancy Childbirth; 2020 May; 20(1):272. PubMed ID: 32375710
[TBL] [Abstract][Full Text] [Related]
20. Familial chylomicronemia syndrome. A sixty year follow-up in two siblings and their kindreds. Nosological and clinical considerations.
Vigna GB; Citroni N; Tarugi P; Fellin R
J Clin Lipidol; 2022; 16(5):591-595. PubMed ID: 35945124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
